News

Hip Fractures Rose in Aged After HT Cessation


 

From the Annual Meeting of the North American Menopause Society

Major Finding: Between July 2002 and December 2008, HT use decreased from 85% to 18% in postmenopausal women over age 60. After adjustment for age and race, women who did not use HT in the previous year had a 55% increased risk of hip fracture. Mean BMD was significantly and inversely associated with cumulative years of HT nonuse.

Data Source: A study of 80,995 patients in the Kaiser Permanente Southern California database.

Disclosures: Dr. Karim said she had no financial conflicts of interest. The study was supported by the University of Southern California.

CHICAGO – Prescriptions for hormone therapy for elderly postmenopausal women declined significantly after the results of the Women's Health Initiative were reported in May 2002, and it now appears that there has been a correspondingly steep rise in hip fracture rates, said Roksana Karim, Ph.D., of the University of Southern California, Los Angeles.

“The rise in hip fracture rates in elderly postmenopausal women may be partially attributed to the continued decline in hormone therapy use,” Dr. Karim said. “Hormone therapy–related benefits on hip fracture do not carry over after cessation.”

This was the conclusion of a longitudinal observational study of 80,995 postmenopausal women aged 60 years or older using data from 11 Kaiser Permanente medical centers in southern California. The study was designed to assess the risk of hip fracture for women who stopped taking hormone therapy (HT), compared with those who continued the therapy. It was also designed to evaluate the risk of hip fracture over time after stopping HT, and to measure bone mineral density (BMD) over time after stopping HT.

Data were collected on hip fracture, HT use, and the use of antiosteoporotic medication from June 2002 through December 2008. All hip fractures were verified by chart review by an orthopedic surgeon who was blinded to patients' HT status. Exclusion criteria included fractures secondary to tumors or high-energy trauma, and periprosthetic fractures. Patients were considered to be HT users if they had filled at least two prescriptions in a given year, as each prescription provides a 3-month supply of medication. HT was defined as estrogen alone or estrogen plus progesterone.

BMD data of the hip and lumbar regions were available for 54,209 women (67%). The 80,955 women had a mean age of 68.8 years and a mean body mass index of 26.9 kg/m

Dr. Karim acknowledged that the study was limited by lack of body mass index data in 47% of the population, or information on history of past HT use or on previous fractures.

The estimated annual cost for osteoporotic fractures in the United States is $18 billion, and hip fractures result in a greater cost and disability than do all other osteoporotic fractures combined. “Women at risk of hip fracture should consider carefully before making a decision of stopping using HT,” she said.

During a question-and-answer session, Andrea LaCroix, Ph.D, professor of epidemiology at the University of Washington, Seattle, said, “It certainly comes as no surprise that women discontinue hormone therapy. There's some loss of bone density and an increase in hip fracture rates. I agree with the conclusion that women coming off hormone therapy should be counseled about their potential for losing bone and having an increased fracture risk, but they've never enjoyed more alternatives for the prevention of hip fracture than they do today, including many agents besides HT.”

'Women at risk of hip fracture should consider carefully before making a decision of stopping using HT.'

Source DR. KARIM

Recommended Reading

WHI: New Findings on Big-Three Cancer Rates
MDedge ObGyn
MRI Bests Mammography for At-Risk Women
MDedge ObGyn
Test Menopausal Women Earlier for Bone Loss
MDedge ObGyn
SWAN: New-Onset Depression at Perimenopause
MDedge ObGyn
Blood Type Tied To Diminished Ovarian Reserve
MDedge ObGyn
MRI Spotted Clinically Occult Breast Cancer
MDedge ObGyn
How to Meet the Challenges of HPV Vaccination
MDedge ObGyn
Hysterectomy Cost: Operative Time Has Big Role
MDedge ObGyn
Robotic Hysterectomy Is Comparable to Other Approaches
MDedge ObGyn
For Endometriotic Pain: Mirena Plus Danazol
MDedge ObGyn